Swiss Multiple Sclerosis Cohort-Study
The Swiss MS Cohort Study (SMSC) is a multicentre cohort study that involves 8 Swiss Multiple Sclerosis centres. The key aims of the SMSC are 1. To maintain a long-term cohort for an undefined duration of patients with Multiple Sclerosis (MS), neuromyelitis optica spectrum disorder (NMOSD) and Myelin oligodendrocyte gl
| Condition(s) | Multiple Sclerosis |
|---|---|
| Status | Recruiting |
| Study type | Observational |
| Summary | The Swiss MS Cohort Study (SMSC) is a multicentre cohort study that involves 8 Swiss Multiple Sclerosis centres. The key aims of the SMSC are 1. To maintain a long-term cohort for an undefined duration of patients with Multiple Sclerosis (MS), neuromyelitis optica spectrum disorder (NMOSD) and Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in Switzerland. This requires effective measures to limit drop-outs and the continuous recruitment of MS patients and 2. To conduct a systematic follow-up with standardized, high quality collection of clinical and magnetic resonance imaging (MRI) data, as well as body fluids. The significant heterogeneity within the diagnostic entity and phenotype of MS is incompletely understood. A central and necessary prerequisite of further a |
| Who can participate | Inclusion Criteria: * Fulfilling the diagnosis of radiologically isolated syndrome (RIS), clinically isolated syndrome (CIS), relapsing-remitting Multiple Sclerosis (RRMS), secondary-progressive MS (SPMS), primary-progressive MS (PPMS), neuromyelitis optica spectrum disorder (NMOSD) or Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) according to established criteria * Intending to attend hospital visits every 6 months (+/- 45 days) or 12 months (+/- 45 days) (facultative cranial MRI every 12 months) over a longer period (at least 5 years) * Intending to give blood for biobanking every 6 or 12 months during hospital visit or as close as possible to the visit (+/- 8 days) Inclusion criteria are crafted to identify a population of patients with MS, NMOSD or MOGAD parti |
| Sex | All |
| Lead sponsor | University Hospital, Basel, Switzerland |
| Locations | Aarau, Canton of Aargau, Switzerland; Basel, Canton of Basel-City, Switzerland; Bern, Canton of Bern, Switzerland; Geneva, Canton of Geneva, Switzerland; Sankt Gallen, Canton of St. Gallen, Switzerland; Lausanne, Canton of Vaud, Switzerland (+2 more sites) |
| Start date | 2012-06 |
| NCT ID | NCT02433028 |
| Official listing | https://clinicaltrials.gov/study/NCT02433028 |